Evonik二季度EBITDA同比增24%并上调2026年指引，但预标PLTR明显误映射

U.S.-Iran talks uncertain; Palantir, Snap report - what’s moving markets
Introduction & Market Context
Evonik Industries presented its second-quarter 2026 results on August 4, 2026, revealing what CEO Christian Kullmann called "the best quarter result in four years." The German specialty chemicals company delivered adjusted EBITDA of €630 million, representing a 24% year-over-year increase, and subsequently raised its full-year outlook considerably. The stock responded positively, trading at $18.015, up 2.42% and near its 52-week high of $18.25.
The strong performance comes amid what the company characterizes as "weak demand and structural headwinds" in the broader chemical sector, highlighting Evonik’s strategic positioning and operational improvements as key differentiators.
Quarterly Performance Highlights
As shown in the following comprehensive dashboard of Q2 2026 results, Evonik delivered across multiple financial metrics:
The company’s second-quarter sales reached €3,893 million, an 11% increase from €3,499 million in the prior-year period. This growth was driven equally by volume and price improvements, with each contributing 7 percentage points, partially offset by a 2% foreign exchange headwind.
The following chart illustrates the progression of adjusted EBITDA and margin performance across recent quarters:
Adjusted EBITDA climbed to €630 million from €509 million in Q2 2025, with the EBITDA margin expanding to 16.2% from 14.5%. The performance was primarily driven by strong results in Advanced Technologies, which saw a 25% year-over-year increase, along with solid performance in Custom Solutions (+7% year-over-year) and higher spreads in the C4 business.
Free cash flow showed dramatic improvement, as illustrated in this quarterly comparison:
Free cash flow reached €49 million in Q2 2026, a substantial turnaround from negative €211 million in the same quarter last year. For the first half of 2026, free cash flow totaled €232 million compared to negative €16 million in H1 2025. This improvement stemmed from better earnings, strict net working capital management, lower bonus payouts, and higher non-cash provisions.
Adjusted earnings per share more than doubled to €0.65 from €0.34 in the prior-year quarter, reflecting the strong operational performance and improved profitability.
Segment Performance Analysis
The following segment overview provides a detailed breakdown of performance across Evonik’s business units:
Advanced Technologies emerged as the star performer, with adjusted EBITDA of €333 million in Q2 2026, up 25% from €266 million in Q2 2025. Sales increased 9% to €1,647 million, with the segment margin expanding to 20.2% from 17.6%. The performance was broad-based across the segment’s three divisions:
- Organics delivered clearly higher EBITDA year-over-year, with High Performance Polymers benefiting from higher capacity utilization following a major shutdown last year, while Crosslinkers capitalized on market momentum
- Animal Nutrition showed ongoing strong price momentum despite slightly lower volumes due to shutdowns, with the backward integration in Mobile completed and showing positive effects
- Inorganics experienced slightly lower EBITDA despite Silica benefiting from network optimization and Hydrogen Peroxide showing good volume growth in semiconductor applications
Custom Solutions posted adjusted EBITDA of €271 million, up 7% from €254 million in Q2 2025, with sales rising 4% to €1,422 million. The segment margin improved to 19.1% from 18.6%. Additives saw good demand excluding Catalysts, partly due to war-related supply chain disruptions, while Catalysts improved after a weak start. The Care division showed favorable price realization in specialties compensating for weak volumes in base ingredients.
Infrastructure and Other segments showed remarkable improvement, with adjusted EBITDA of €26 million compared to negative €11 million in Q2 2025, representing a 163% increase. This was driven primarily by Oxeno’s C4 business, which benefited from higher margins due to the war in the Middle East.
Strategic Initiatives
Evonik presented its strategic framework contrasting current challenges with future opportunities:
The company emphasized that despite operating in an environment of weak demand and structural headwinds, it is "acting from a position of strength" supported by industry-leading cash generation and moderate leverage. The strategic focus centers on consistent cost reduction, portfolio optimization, growth in attractive niches, and more balanced use of cash, with a target return on capital employed (ROCE) of approximately 11%.
Central to this strategy is the extended Evonik Tailor Made efficiency program, detailed in the following timeline:
The efficiency program has been extended through 2029, with an additional 3,200 full-time equivalent (FTE) positions targeted for reduction beyond the initial program. The original 2023-2026 phase focused on reorganization, business optimization, and procurement optimization, targeting approximately 2,000 FTE reductions with €400 million in gross savings (80% from personnel costs). Employee numbers have declined from 31,930 in 2024 to an estimated 30,000 for 2026.
The 2027-2029 extension takes a more holistic approach, bundling all cost savings and optimization measures for more efficient steering. The additional 3,200 FTE reductions will cover both administrative (approximately 60%) and operative roles (approximately 40%), utilizing HR tools such as early retirement packages, internal relocation, and natural fluctuation, while leveraging increased efficiency and digitalization.
The company is also pursuing targeted business optimization programs across six key areas, as shown in this comprehensive update:
These programs span Amino Acids, High Performance Polymers, Silica/Silanes, Coating & Adhesive Resins, Health Care, and Crosslinkers, with initiatives including site closures (Havre de Grace, Waterford, Leverkusen, Witten, and Hanau), backward integration in the U.S. for amino acids (completed), and various portfolio and production optimizations. All programs are reported as ongoing and on track.
Evonik also highlighted its innovation pipeline with market-ready solutions across three strategic growth areas:
These include Ecobiol® probiotics for livestock production (advancing precision biosolutions), specialized catalysts and adsorbents for chemical recycling of plastics (enabling circular economy), and DURAION® membranes for cost-competitive green hydrogen production (accelerating energy transition).
Forward-Looking Statements
Based on the strong first-half performance, Evonik raised its full-year 2026 outlook considerably, as illustrated in this guidance comparison:
The company now expects adjusted EBITDA between €2.0 billion and €2.2 billion for full-year 2026, up from the previous range of €1.7 billion to €2.0 billion and compared to €1.9 billion in 2025. This represents a €250 million increase at the midpoint of guidance.
By segment, the outlook calls for:
- Custom Solutions: Stable on prior-year level (2025: €909 million)
- Advanced Technologies: Considerably above prior-year level (2025: €944 million)
- Infrastructure (including C4) / Other: Significantly above prior-year level (2025: €21 million)
Additional financial indications for FY 2026 are detailed in the following table:
Key guidance metrics include sales of around €15 billion (previously €13.5-14.5 billion), ROCE slightly above the prior-year level of 6.1%, capital expenditure of approximately €750 million, and an adjusted tax rate of around 25% (reduced from the long-term sustainable level of approximately 30% due to higher earnings share in countries with lower tax rates).
The company confirmed its free cash flow outlook, targeting approximately 40% conversion for FY 2026, supported by better operating results, disciplined capital expenditure, lower bonus payments, and net working capital management despite some headwind from inflation.
The detailed adjusted income statement for Q2 2026 shows the earnings progression:
Adjusted income after taxes reached €297 million in Q2 2026, an 81% increase from €164 million in Q2 2025, while adjusted net income climbed 85% to €296 million from €160 million. The adjusted tax rate of 18% in Q2 was lower than the long-term average due to a higher earnings share in countries with lower tax rates. Adjustments totaling negative €207 million included €48 million for restructuring (especially provisions for Witten site closure) and €159 million for other special items (mainly impairment of the Oxeno C4 business).
CEO Christian Kullmann emphasized the company’s balanced approach, stating, "We control our own destiny – acting from a position of strength," while also noting that "we are not resting on this short-term success" given ongoing structural challenges in the chemical sector.
CFO Michael Rauch highlighted that the first-half performance provides "strong underpinning" for the full-year guidance, with the company having delivered €1.1 billion in adjusted EBITDA in H1 2026, requiring another €1 billion in the second half to reach the midpoint of the upgraded outlook.
Management indicated that Q3 should remain strong and could be similar to Q2 or slightly better, particularly for methionine in Animal Nutrition. However, the company expects a more pronounced normalization in the fourth quarter, consistent with typical seasonal patterns and market conditions.
The presentation emphasized that Evonik expects "at least some demand improvement" in coming years and has "more potential for improvement with our strategy execution," positioning the company for continued progress toward its ROCE target of approximately 11%.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.